Skip to content
10-Q

Quarterly Report

MYRIAD GENETICS INC MYGN

0000899923-25-000048

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 92.18M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $59.3M
Long Term Debt Q1 2025 · Dec 31, 2024 $39.6M
Current Liabilities Q1 2025 · Mar 31, 2025 $151.1M
Current Liabilities Q1 2025 · Dec 31, 2024 $164.1M
Total Liabilities Q1 2025 · Mar 31, 2025 $301.2M
Total Liabilities Q1 2025 · Dec 31, 2024 $326.5M
Current Assets Q1 2025 · Mar 31, 2025 $287.2M
Current Assets Q1 2025 · Dec 31, 2024 $298M
Total Assets Q1 2025 · Mar 31, 2025 $1.01B
Total Assets Q1 2025 · Dec 31, 2024 $1.03B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $102.4M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $96.9M
Shares Diluted Q1 2025 · Mar 31, 2024 89.9M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$18.6M
Stockholders Equity Q1 2025 · Mar 31, 2024 $760M
Stockholders Equity Q1 2025 · Dec 31, 2023 $783.2M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.29
Eps Basic Q1 2025 · Mar 31, 2024 −$0.29
Rd Expense Q1 2025 · Mar 31, 2024 $24.9M
Net Income Q1 2025 · Mar 31, 2024 −$26M
Operating Income Q1 2025 · Mar 31, 2024 −$27.9M
Gross Profit Q1 2025 · Mar 31, 2024 $137.6M
Revenue Q1 2025 · Mar 31, 2024 $202.2M